there is no diversion on how sector stated, no more CR will be needed, everything is fully funded. he hasn’t and can’t defend it!
the lead products in Covid and gvhd have gone nowhere. I think they are waiting for MSB to show their hand on Covid so they can copy. That’s what they’ve poorly done to date.
Gvhd no show is very strange. And now msb will be going after adults earlier. Is this lead product dead?
OA - I have my reservation on skipping ahead to p3, that’s concerning for anyone with knowledge of how these things work, and cartilage growth expectations is a concern. the measurement of such is inconclusive and much debate exists on using this as a method of measuring success. In fact MSB dumped it.
on your wider post, of 6-8 trials getting up. Everyone has reservations on managements ability to achieve. Will this continue or much of the same.
CYP Price at posting:
63.5¢ Sentiment: Hold Disclosure: Not Held
(20min delay)